279: Live from the 2023 STAT Summit
Live from Boston at the 2023 STAT Summit, we discuss the latest news in the life sciences, including a milestone in genome editing, a twist in the search for ALS treatments, and the polarizing process...
19 Okt 202333min
278: Merger Mondays, Ozempic panic, & CRISPR'd pigs
We discuss Bristol Myers Squibb’s multibillion-dollar acquisition of Mirati Therapeutics and what it means for a biotech sector still in a slump. We also explain the latest news in the life sciences, ...
12 Okt 202332min
277: Is the Nobel committee evolving? Plus, preventing public health's wiliest virus
It’s Nobel week on the podcast, and reporter Megan Molteni details the unique story of this year’s winners for medicine, Katalin Karikó and Drew Weissman. Then, our colleague Jason Mast joins us to ex...
5 Okt 202331min
276: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech's slump
Our colleague Elaine Chen joins us to explain the story of Svetlana Mojsov, a chemist who played a vital role in the discovery of GLP-1 who has spent decades fighting for proper recognition. We also d...
28 Sep 202334min
275: A thorny ALS debate at the FDA, and the promise of artificial wombs
Our colleague Lizzy Lawrence joins us to explain the promise of artificial wombs and the debate over how to ethically develop them. We also discuss a momentous upcoming meeting in which FDA will consi...
21 Sep 202333min
274: Covid’s latest surge, Alnylam at the FDA, & the end of an era
Our colleague Helen Branswell joins us to discuss the state of the Covid-19 pandemic heading into the fall and the rollout of boosters shots aimed at the latest viral variants. We also discuss the lat...
14 Sep 202339min
273: Back to school for biotech, Biogen's potential pivot, & Illumina's next chapter
Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the late...
7 Sep 202333min
272: Vivek's star turn, leaky drug data, & biotech as family business
We discuss how Vivek Ramaswamy, fresh off his headline-grabbing debut at the first Republican presidential debate, went from a drug industry entrepreneur to a GOP rising star — and how his former biot...
24 Aug 202329min
